IP Library › Granted Patent US 12,203,940
Granted Patent B2
US 12,203,940 · App. 17/812,537 · Granted Jan 21, 2025

Biomarkers for diagnosing implant related risk of implant revision due to aseptic loosening

Inventors: Stein Lian (Kvaloya, NO); Jarle Mikalsen (Tromsdalen, NO); Eric Bendiksen (Krokelvdalen, NO); Anders Einung Hansen (Tromso, NO)
Assignee: Lyfstone B.V.
G01N33/6887G01N2333/4727G01N2800/108G01N2800/52G01N2800/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,203,940
App. No.
17/812,537
Granted
Jan 21, 2025
Kind
B2
Abstract

Implant related risk of revision not caused by an infection or metal on metal reaction can be addressed by the methods provided herein, including diagnosing implant related risk of revision, use of kits for such diagnostic purposes and compositions for use in the treatment of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction.

Claims (15)

1. A method of identifying implant related risk of revision, the method comprising:

providing a biological sample from a human subject with an implant; and

detecting a level of a protein in the biological sample, wherein the level of the protein is at least 4 mg/l, wherein the protein comprises calprotectin, wherein the biological sample comprises synovial fluid, and wherein the implant comprises a joint implant.

2. The method of claim 1 , wherein the synovial fluid is collected at the site of the joint implant.

3. The method of claim 1 , wherein the protein in the biological sample is a secreted protein and not an intracellular protein of intact cells present in the biological sample.

4. The method of claim 1 , wherein the level of the protein is 4 mg/l to 50 mg/l.

5. The method of claim 1 , wherein the joint implant comprises a joint prosthesis.

6. The method according to claim 1 , wherein the biological sample is not subjected to treatment which would cause release of intracellular S100A8, S100A9, or calprotectin into the biological sample.

7. The method according to claim 1 , wherein the subject is asymptomatic.

8. The method according to claim 1 , wherein the synovial fluid is hip-joint synovial fluid.

9. The method according to claim 1 , wherein the synovial fluid is knee joint synovial fluid.

10. The method according to claim 1 , wherein the implant related risk of revision is pathology initiation or acute pathology.

11. The method of claim 1 , wherein the joint implant comprises a hip replacement implant.

12. The method of claim 1 , wherein the joint implant comprises a knee replacement implant.

13. The method of claim 1 , wherein the level of the protein is greater than 50 mg/l.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2022
From: LYFSTONE AS
To: LYFSTONE B.V.
Reel/Frame 060873/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2022
From: LIAN, STEIN; MIKALSEN, JARLE; BENDIKSEN, ERIC; HANSEN, ANDERS EINUNG
To: ORTHOGENICS AS
Reel/Frame 060676/0089 →
CHANGE OF NAME Recorded Jul 29, 2022
From: ORTHOGENICS AS
To: LYFSTONE AS
Reel/Frame 061032/0850 →
Priority Claims (1)
NO 20170185 · Feb 7, 2017 · national
Continuity (2)
Continuation 16483784
Related Publication 20230081885A1 · Mar 16, 2023
References Cited (32)
US 5776348A · Selengut et al. · 1998 [cited by applicant]
US 11402389B2 · Lian · 2022 [cited by examiner]
US 20050288211A1 · Tessier et al. · 2005 [cited by applicant]
US 20060105419A1 · Blankenberg · 2006 [cited by examiner]
US 20060134705A1 · Sundrehagen · 2006 [cited by applicant]
US 20150110811A1 · de Min et al. · 2015 [cited by applicant]
EP 0585201 · 1994 [cited by applicant]
RU 2305285 · 2007 [cited by applicant]
WO WO2006047820 · 2006 [cited by applicant]
WO WO2008114022 · 2008 [cited by applicant]
WO WO2017023929A1 · 2017 [cited by examiner]
Dhas et al., Role of Calprotectin in Infection and Inflammation, Curr Pediatr Res 2012; 16(2), pp. 83-94. (Year: 2012). [cited by examiner]
Berntzen et al., “The Major Leukocyte Protein L 1 as an Indicator of Inflammatory Joint Disease”, Sc and J Rheumatology, Suppl. vol. 76, 1988, pp. 251-256. [cited by applicant]
Dapunt et al., “Neutrophil-derived MRP-14 is up-regulated in infectious osteomyelitis and stimulates osteoclast generation”, Journal of Leukocyte Biology, vol. 98, Oct. 2015, p. 575-582. [cited by applicant]
Dapunt et al., “On the inflammatory response in metal-on-metal implants”, Journal of Translational Medicine, vol. 12, No. 1, 2014, p. 74. [cited by applicant]
Dapunt et al., “Osteoclast generation and cytokine profile at prosthetic Interfaces: a study on tissue of patients with aseptic loosening or implant-associated infections”, European Journal ofInflammation, vol. 12, No. … [cited by applicant]
International Search Report issued Jul. 26, 2018 in International (PCT) Application No. PCT/EP2018/053044. [cited by applicant]
Kessel et al., “Phagocyte-derived S 100 proteins in auto inflanunation: Putative role in pathogenesis and usefulness as biomarkers”, Clinical Immunology, vol. 147, 2013, pp. 229-241. [cited by applicant]
Klingberg et al., Calprotectin in ankylosing spondylitis—frequently elevated in feces, but normal in serum, Scandinavian Journal of Gastroenterology, 2012; 47: pp. 435-444. (Year: 2012). [cited by applicant]
Nordal et al., “Calprotectin (SIO0A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheum… [cited by applicant]
Office Action issued in AU application No. 2018217872, dated Nov. 30, 2020. [cited by applicant]
Office Action issued in corresponding CN application No. 201880022814.1, dated Apr. 15, 2022. [cited by applicant]
Office Action issued in EP application No. 18707053.6, dated Jun. 25, 2021. [cited by applicant]
Office Action issued in EP application No. 18708053.6, dated Jul. 27, 2020. [cited by applicant]
Office Action issued in EP application No. 18708053.6, dated Nov. 27, 2020. [cited by applicant]
Office Action issued in RU application No. 2019126238/04, dated May 28, 2021. [cited by applicant]
Response to Office Action issued in EP application No. 18708053.6, filed Sep. 30, 2020. [cited by applicant]
Response to Office Action issued in EP application No. 18708053.6, filed Mar. 25, 2021. [cited by applicant]
Schelbergen et al., “Alarmins SIO0A8/SIO0A9 aggravate osteophyte formation in experimental osteoarthritis and predictosteophyte progression in early human symptomatic osteoarthritis”, Ann Rheum Dis vol. 75, 2016, pp. 21… [cited by applicant]
Sumner et al., “Are There Biological Markers for Wear or Corrosion? A Systematic Review”, Clin. Orthop. Relat. Res., vol. 472, 2014, pp. 3728-3739. [cited by applicant]
Torzewski et al., Animal Models of C-Reactive Protein, Hindawl Publishing Corporation, Mediators of Inflammation, 2014, pp. 1-7. (Year: 2014). [cited by applicant]
Van Der Vekiens et al., Human and equine cardiovascular endocrinology: beware to compare, Cardiovascular Endocrinology 2013, vol. 2, No. 4, pp. 67-76. (Year: 2013). [cited by applicant]